ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 3ÔÂ25ÈÕ£¬£¬£¬·²¶÷ÊÀ£¨Phanes Therapeutics£©Ðû²¼£¬£¬£¬ÃÀ¹úFDAÊÚÓèÆäPT886¿ìËÙͨµÀ×ʸñ£¬£¬£¬ÓÃÓÚÖÎÁÆ×ªÒÆÐÔClaudin 18.2ÑôÐÔÒÈÏÙ°©»¼Õß¡£¡£¡£¡£¡£´Ëǰ£¬£¬£¬PT886ÒÑÓÚ2022Äê»ñµÃÁËFDAÊÚÓèÓÃÓÚÖÎÁÆÒÈÏÙ°©µÄ¹Â¶ùÒ©×ʸñ£¬£¬£¬²¢ÓÚ½ñÄê2ÔÂÔÚÖйú»ñÅú¿ªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£¡£¡£
2. 3ÔÂ25ÈÕ£¬£¬£¬¹ãÖÝÈüöÁÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾×ÔÖ÷Ñз¢µÄCG-BM1ÒìÌåÈ˹ÇËè¼ä³äÖʸÉϸ°û×¢ÉäÒº£¬£¬£¬Õýʽ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐĵÄÒ©ÎïÁÙ´²ÊÔÑéÅú×¼£¬£¬£¬»ñÅúµÄÁÙ´²Ñо¿Ë³Ó¦Ö¢Îª£ºÈ±ÑªÐÔÄÔ×äÖС£¡£¡£¡£¡£
3. 3ÔÂ24ÈÕ£¬£¬£¬Ô¶´óÒ½Ò©Ðû²¼ÆäÁ¢Òì·ÅÉäÐÔºËËØÅ¼ÁªÒ©ÎRDC£©ITM-11ÒÑ»ñµÃÖйú¹ú¼ÒÒ©¼à¾Ö£¨NMPA£©Åú×¼¿ªÕ¹3ÆÚÁÙ´²Ñо¿£¬£¬£¬Ä⿪·¢ÓÃÓÚÖÎÁÆÎ¸³¦ÒÈÏÙÉñ¾ÄÚÉøÍ¸Áö£¨GEP-NETs£©»¼Õß¡£¡£¡£¡£¡£
4. ¿ËÈÕ£¬£¬£¬¾ÝCDE¹ÙÍøÏÔʾ£¬£¬£¬ËÄ´¨¿µµÂÈüÒ½ÁƿƼ¼ÓÐÏÞ¹«Ë¾µÄ¡°CUD005×¢ÉäÒº¡±ÒѾ»ñÅúÁÙ´²ÊÔÑéĬʾÔÊÐí¡£¡£¡£¡£¡£CUD005×¢ÉäÒºÊÇÒ»¿î»ùÓÚ»¼Õß×ÔÉíÃâÒßϸ°û£¬£¬£¬Ë³Ó¦Ö¢ÎªÊ§´ú³¥ÆÚ¸ÎÓ²»¯¡£¡£¡£¡£¡£
1. 3ÔÂ24ÈÕ£¬£¬£¬È«ÇòÒ½Ò©¾ÞÍ·°¢Ë¹Àû¿µCEOËÕ²©¿ÆÐû²¼£¬£¬£¬¹«Ë¾ÒÑÔÚÖйúÇൺºÍÎÞÎý»®·ÖͶ×Ê7ÒÚÃÀÔªºÍ4.75ÒÚÃÀÔªÓÃÓÚн¨Ò©Î﹤³§¡£¡£¡£¡£¡£Çൺ¹¤³§½«³ÉΪ°¢Ë¹Àû¿µÈ«Çò×î´óµÄÉú²ú»ùµØÖ®Ò»£¬£¬£¬Ö÷ÒªÊÇÉú²úÎüÈëÆøÎí¼Á£¬£¬£¬¶øÎÞÎý¹¤³§ÔòרעÓÚÉú²úÁ¢ÒìÒ©Îï¡£¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬¡¶ÃÀ¹úҽѧ»áÔÓÖ¾¡·£¨JAMA£©½ÒÏþµÄÒ»ÏîÑо¿£¬£¬£¬Åú×¢Ïà±ÈÓÚο½å¼Á£¬£¬£¬ÖðÈÕʹÓõͼÁÁ¿µÄ°¢Ë¾Æ¥ÁÖÖÎÁÆ6¸öÔº󣬣¬£¬MASLD»¼Õ߸ÎÔàÖ¬·¾º¬Á¿ÏÔÖø½µµÍ¡£¡£¡£¡£¡£Î´À´ÓÐÐëÒªÔÚ¸ü´óµÄÈËȺÖпªÕ¹½øÒ»²½Ñо¿£¬£¬£¬ÒÔ×ôÖ¤±¾´ÎÑо¿µÄ·¢Ã÷¡£¡£¡£¡£¡£
[1] Simon TG, Wilechansky RM, Stoyanova S, et al. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial. JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215. PMID: 38502074.
Ïà¹ØÐÂÎÅʱ¼ä£º2020Äê12ÔÂ09-10ÈÕ
ËùÔÚ£ºÉϺ£ÆÖ¶«Â̵ز¬æêÂùÝ
ʱ¼ä£º2020Äê09ÔÂ03ÈÕ
ËùÔÚ£ºÏßÉÏÖ±²¥